verapamil has been researched along with Cold Fingers, Hereditary in 12 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on their previous observations of the stimulating action of verapamil on the secretory reserve of cortisol after one-week oral administration to healthy volunteers, the author investigated the effect of this calcium entry blocker on the adrenocortical function (cortisol and aldosterone secretion) during therapeutic administration to patients with mild arterial hypertension and normotensive patients suffering from Raynaud's syndrome." | 3.67 | The effect of long-term verapamil treatment on the secretion of cortisol and aldosterone in subjects with normal and high blood pressure. ( Zofková, I, 1985) |
| "Verapamil was evaluated in 16 patients with severe Raynaud's phenomenon." | 2.65 | The treatment of severe Raynaud's phenomenon with verapamil. ( Gallo, J; Kinney, EL; Nicholas, GG; Pontoriero, C; Zelis, R, 1982) |
| "Verapamil was least efficient and exerted a weak vasoactive action." | 1.27 | [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists]. ( Shcherbakov, AB, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (66.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auboire, L | 1 |
| Landy, S | 1 |
| Perrot, JY | 1 |
| Maïza, D | 1 |
| Le Hello, C | 1 |
| Chu, ER | 1 |
| Lee, AW | 1 |
| Chen, CS | 1 |
| Zofková, I | 2 |
| Hampl, R | 1 |
| Roztocil, K | 1 |
| Kochar, MS | 1 |
| Kinney, EL | 1 |
| Nicholas, GG | 1 |
| Gallo, J | 1 |
| Pontoriero, C | 1 |
| Zelis, R | 1 |
| Lazareth, I | 1 |
| Gallacher, BP | 1 |
| Ackerman, Z | 1 |
| Lysy, J | 1 |
| Meiner-Lavie, V | 1 |
| Shcherbakov, AB | 2 |
| Guseva, NG | 1 |
| Mach, ES | 1 |
| Smith, CR | 1 |
| Rodeheffer, RJ | 1 |
3 reviews available for verapamil and Cold Fingers, Hereditary
| Article | Year |
|---|---|
[A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Ne | 2010 |
[Management of Raynaud's phenomenon].
Topics: Adult; Age Distribution; Calcium Channel Blockers; Female; Humans; Iloprost; Losartan; Male; Middle | 2001 |
Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Female; Humans; | 1985 |
3 trials available for verapamil and Cold Fingers, Hereditary
| Article | Year |
|---|---|
The treatment of severe Raynaud's phenomenon with verapamil.
Topics: Clinical Trials as Topic; Double-Blind Method; Hemodynamics; Humans; Raynaud Disease; Verapamil | 1982 |
[Treatment of Raynaud's syndrome with calcium entry blockers].
Topics: Adolescent; Adult; Calcium Channel Blockers; Clinical Trials as Topic; Female; Fendiline; Humans; Ma | 1987 |
Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Female; Humans; | 1985 |
7 other studies available for verapamil and Cold Fingers, Hereditary
| Article | Year |
|---|---|
Resolution of visual field constriction with verapamil in a patient with bilateral optic neuropathy, migraine and Raynaud's phenomenon.
Topics: Adult; Female; Humans; Migraine Disorders; Optic Nerve Diseases; Raynaud Disease; Treatment Outcome; | 2009 |
Adrenocortical function in the course of long-term verapamil treatment.
Topics: Adrenal Cortex; Adult; Aldosterone; Female; Humans; Hydrocortisone; Hypertension; Male; Middle Aged; | 1984 |
Simultaneous treatment of Raynaud's phenomenon and orthostatic hypotension.
Topics: Drug Therapy, Combination; Ephedrine; Female; Fludrocortisone; Follow-Up Studies; Humans; Hydralazin | 1983 |
Intra-arterial verapamil to reverse acute ischaemia of the hand after radial artery cannulation.
Topics: Aged; Arteries; Catheterization, Peripheral; Hand; Humans; Injections, Intra-Arterial; Ischemia; Mal | 1991 |
The association of fecal impaction and verapamil in a patient with scleroderma.
Topics: Adult; Constipation; Fecal Impaction; Female; Humans; Raynaud Disease; Scleroderma, Systemic; Verapa | 1989 |
The effect of long-term verapamil treatment on the secretion of cortisol and aldosterone in subjects with normal and high blood pressure.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Aldosterone; Female; Humans; Hydrocortisone; Hyp | 1985 |
[Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].
Topics: Blood Circulation; Calcium Channel Blockers; Connective Tissue Diseases; Drug Evaluation; Fendiline; | 1988 |